Vantage logo

Pharma news over the Christmas period

If the recent performance of biotech stocks prompted you to pull down the shutters until the New Year celebrations subsided here’s what you might have missed.

Vantage logo

Death of a unicorn

Moderna’s upsized IPO is the biggest-ever for a pre-commercial biotech. But its share price has fallen in early trade on its first day.

Vantage logo

China comes of age

Chi-Med is not alone in seeing Chinese approval as the prelude to a regulatory green light in the west.